Cellarity, a clinical-stage, biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced acceptance of two oral presentations on ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...

Details regarding the oral presentation can be found below. Abstract Title: Accelerating Access to Gene Therapy: Lessons from Commercial Implementation in Sickle Cell Disease and Transfusion-Dependent ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...

Thousands of Californians live with sickle cell disease, a painful blood disorder. But new treatments, including a promising form of gene therapy, are offering hope to ...

CIRM awards $27 million to launch novel program designed to bring cell and gene therapies to underserved California communities ...

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Beam Therapeutics, Inc. (($BEAM)) announced an update on their ongoing clinical study. Beam Therapeutics, Inc. is conducting the BEACON trial, ...